|
|||||
|
Boston Scientific Begins Exclusive International Distribution of NexStent™ Carotid Stent |
|||||
|
Innovative stent technology, combined
with Boston Scientific's embolic protection device,
offers less-invasive option for treating carotid artery disease |
|||||
NATICK, Mass., April 13 -- Boston Scientific Corporation (NYSE: BSX - News) today announced that it is now acting as the exclusive distributor of the NexStent™ carotid stent and Monorail™ delivery system in Europe and certain other international markets. The NexStent™ Monorail™ system, developed and manufactured by EndoTex Interventional Systems, Inc., recently received CE Mark for commercialization in Europe and certain other international markets. It has not yet been approved for commercialization in the United States. "Our alliance with EndoTex demonstrates Boston Scientific's ability to provide the most innovative technology to our customers quickly," said Matthew Jenusaitis, President of Boston Scientific's Peripheral Interventions business. "The NexStent carotid stent, used in combination with the Boston Scientific FilterWire EZ™ embolic protection system, offers patients a less-invasive treatment alternative to the traditional surgical procedure known as a carotid endarterectomy." "We have enjoyed a productive relationship with Boston Scientific as we collaborated on the CABERNET trial and now as we launch the NexStent in Europe," said Joseph Tartaglia, Chief Executive Officer and President of EndoTex Interventional Systems, Inc. "We are proud of our team's efforts and look forward to continued success as we work to launch this technology in the United States early next year." The NexStent Carotid Stent consists of a laser-cut, rolled sheet of nitinol. The rolled sheet design enables the stent to adapt to multiple diameters and in tapered or non-tapered configurations, providing customized treatment of stenotic lesions in the carotid arteries. It joins Boston Scientific's Carotid Wallstent™ Monorail™ -- a self-expanding, self- tapering stent constructed of a cobalt-chromium alloy braided mesh -- to provide physicians in Europe and certain other international markets a variety of stent options for the treatment of carotid artery disease. The carotid arteries, located on either side of the neck, are the main conduit for blood flow to the brain. Plaque formation in these arteries can lead to carotid artery disease, putting these patients at risk for stroke. Most patients with a narrowing of their carotid arteries are treated by carotid endarterectomy, which involves a vertical incision in the neck through which the plaque is removed. Carotid artery stenting is a less-invasive alternative in which a stent is fed to the site of the blockage on a catheter inserted through a small incision in the groin. At the site of the blockage, the stent is expanded where it forces the walls of the arteries open, allowing blood flow to resume. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com. This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, intellectual property, regulatory approvals, competitive offerings, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.
|